A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder.

@article{Waxmonsky2011ACO,
  title={A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder.},
  author={James G. Waxmonsky and Daniel A. Waschbusch and Opeoluwa Akinnusi and William E. Pelham},
  journal={Journal of child and adolescent psychopharmacology},
  year={2011},
  volume={21 1},
  pages={
          21-32
        }
}
OBJECTIVE This secondary analysis examined the efficacy and tolerability of atomoxetine (ATX) dosed once (QD) versus twice (BID) daily in 55 children aged 6-12 with attention-deficit/hyperactivity disorder (ADHD). METHODS The original 8-week trial was designed to assess the benefits of adding behavioral therapy to ATX. In it, all subjects were treated openly with ATX, with 50% randomly assigned to additional behavioral treatments. Every subject was started on QD dosing with a target dose of 1… 

Figures and Tables from this paper

The Efficacy of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Clinical Research

Overall, these papers demonstrate that atomoxetine is an effective treatment for the core ADHD symptoms, and improves functional outcomes and quality of life, in various pediatric populations with ADHD, and it is important that the clinician sets appropriate expectations with regard to the likelihood of a gradual response, which often builds over time.

Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder.

GXR adjunctive to a psychostimulant significantly reduced oppositional symptoms in subjects with ADHD and a suboptimal response to psychostIMulant alone.

Efficacy and Safety of Atomoxetine in the Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder

An updated summary of the literature on atomoxetine is provided, particularly in relation to findings on the short- and long-term safety of atomoxettine in children and adolescents arising from recent large longitudinal cohort studies.

A Review of Pharmacological Management of Attention-Deficit/Hyperactivity Disorder.

  • L. BriarsTimothy J. Todd
  • Psychology, Medicine
    The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
  • 2016
This review focuses on the clinical use of psychostimulant medication in children and adolescents and the pharmacodynamic and pharmacokinetic differences between the newest long-acting formulations as well as commonly encountered adverse drug reactions.

Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: Focus on clinical efficacy and safety

Using minimum 6-week clinical trial criteria, atomoxetine may demonstrate similar efficacy to methylphenidate comparing reduction in core ADHD symptoms in meta-analysis, although the diversity of the data makes interpretation complex.

Pediatric Psychopharmacology for Treatment of ADHD, Depression, and Anxiety

Basic clinical pharmacology of stimulant and nonstimulant attention-deficit/hyperactivity disorder medications and selective serotonin reuptake inhibitors is provided to serve as a primer for the general pediatrician.

Electroencephalogram activity in attention-deficit hyperactivity disorder

It is found that the score of the KSADS-PL rating scale was significantly decreased in ADHD patients after treatment in both pharmacotherapy groups and there was no significant difference in EEG between both ADHD children before and after treatment.

Pharmacotherapy for attention-deficit/hyperactivity disorder

  • Bongseog Kim
  • Medicine, Psychology
    Journal of the Korean Medical Association
  • 2019
Clinicians should try to develop rapport with patients and their caregivers to increase the likelihood that they will follow the diagnostic process and treatment, and the use of long-acting stimulants is increasing.

Pharmacological Treatment of Attention Deficit Hyperactivity Disorder in Children and Adolescents: Clinical Strategies

Important aspects of evaluation and assessment are reviewed and first-line pharmacological treatments are discussed and as well as when to consider using alternative pharmacological agents are discussed.

The Guideline of Diagnosis and Treatment of Attention-Deficit Hyperactivity Disorder: Developed by ADHD Translational Research Center

Table 1에 정리하였다. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits

References

SHOWING 1-10 OF 42 REFERENCES

Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study

Once-daily administration of atomoxetine is an effective treatment for children and adolescents with attention deficit hyperactivity disorder (ADHD) as assessed by investigator, parent, and teacher ratings.

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.

Among children and adolescents aged 8 to 18, atomoxetine was superior to placebo in reducing ADHD symptoms and in improving social and family functioning symptoms.

High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses.

In both studies, continued treatment, whether at a higher dose or the previous dose, was associated with improved outcomes in patients who demonstrated incomplete/inadequate response to acute ADHD treatment, although without a placebo arm, it cannot rule out the possibility that expectancy played a role in symptom improvement.

Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder.

Atomoxetine improved ADHD symptoms and classroom functioning as measured by parents, teachers, and direct observation and was associated with significant improvements in ADHD and oppositional defiant disorder symptoms at home and school and enhanced functioning in both domains.

Once-Daily Atomoxetine for Treating Pediatric Attention-Deficit/Hyperactivity Disorder: Comparison of Morning and Evening Dosing

Morning dosing was superior to evening dosing on some efficacy measures and Evening dosing showed greater tolerability with significantly more patients receiving morning atomoxetine reporting at least 1 adverse event than those receiving evening atomxetine.

Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

All 3 lisdexamfetamine doses were significantly more effective than placebo in the treatment of adults with ADHD, with improvements noted within 1 week.

Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.

Youths with ADHD and comorbid ODD showed statistically significant improvement in ADHD, ODD, and quality-of-life measures, although the COMorbid group may require higher doses of atomoxetine.

Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine.

When starting atomoxetine, the risk of adverse events within the first few weeks of treatment may be lower if patients are dosed twice daily and titrated to the 1.2 mg/kg/day total daily dose over the first week.

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

Two studies early in its development confirmed that atomoxetine, a specific and selective inhibitor of noradrenergic uptake, was effective for the treatment of children with ADHD and was found to be well tolerated.

Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study.

The recommendation to consider either augmenting or switching treatment in patients who do not achieve at least this level of response to atomoxetine by 4 weeks offers a method for limiting the extended duration of titration to subjects who are most likely to benefit further, while minimizing the duration of exposure in those less likely to achieve an excellent response.